Abstract: A process for producing furfural and levulinic acid from lignocellulose-comprising biomass is disclosed. The biomass is slurried using water and optionally an acid, subjected to hydrolysis, and then subjected to a solid/liquid separation to yield at least an aqueous fraction comprising C5 and C6 sugars and a solid fraction comprising cellulose and lignin. Furfural is obtained by adding an organic solvent to the aqueous fraction, heating at 120-220° C. for a sufficient time to form furfural, cooling, and separating an organic phase comprising at least part of the furfural from an aqueous phase. Levulinic acid is obtained by suspending the solid fraction in water and optionally an acid, heating the suspension to 140-220° C., and separating an aqueous fraction comprising the levulinic acid from a solid fraction.

Abstract: The present invention is directed to a novel crystalline form of (2S)-(?)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse; or for neuroprotection. The present invention is further directed to a process for the preparation of the novel crystalline form.

Abstract: In one aspect, the present invention provides a contrast enhancement agent comprising an iron chelate having structure I and salts thereof wherein R1 is independently at each occurrence a hydroxy group, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, and b is 0-4; R2-R7 are independently at each occurrence hydrogen, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, with the proviso that at least one of R1-R7 is a hydroxy group or a C1-C3 hydroxyalkyl group; and wherein Q is one or more charge balancing counterions. Also provided are a metal chelating ligand having structure IX and medical formulations comprising the contrast enhancement agent I.

Abstract: A compound having the formula: is useful in the preparation of compounds of Formula I.

Abstract: Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a schweinfurthin or schweinfurthin analog or derivative, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Also disclosed is a new schweinfurthin compound of the formula.

Abstract: The present invention relates to compounds with a dioxane nucleus derived from carbohydrates and C-glucosides, process for obtaining same, to the use of such compounds as cytotoxic and antiproliferative agents and to the use thereof for producing a cancer treatment drug.

Abstract: The present invention relates to the scaled-up synthesis of biologically active compounds which display useful therapeutic activity in treating proliferative disorders. In particular the invention relates to process methods for the kilogram scale synthesis of a particular class of substituted benzofuran tubulin polymerisation inhibitors.

Abstract: Disclosed are novel gamma secretase inhibitors of the formula. Also disclosed are methods of inhibiting gamma-secretase, methods of treating neurodegenerative diseases, and methods of treating Alzheimer's Disease. Also disclosed are processes for preparing alkenes in one reaction step using a mixture of an aldehyde (or ketone) and an alkyl substituted with two electron withdrawing groups, and reacting the mixture with: (a) a sulfonyl halide (e.g., a sulfonyl chloride) and a basic tertiary amine, or, (b) a sulfonyl anhydride and a basic amine, or (c) an aryl-C(O)-halide and a basic tertiary amine, or (d) an aryl-C(O)—O—C(O)-aryl and a basic tertiary amine, or (e) an heteroaryl-C(O)-halide and a basic tertiary amine, or (f) a heteroaryl-C(O)—O—C(O)-heteroaryl and a basic tertiary amine.

Abstract: Described is a process to make hydroxymethylfurfural (HMF) from glucose. The process includes the steps of reacting a feedstock solution comprising glucose, in the presence of a homogeneous Brønsted acid catalyst and a homogeneous Lewis acid catalyst, in a reaction vessel containing a biphasic reaction medium. The reaction medium includes an aqueous reaction solution and a substantially immiscible organic extraction solution. HMF is produced in the aqueous reaction solution and extracted into the organic extraction solution.

Abstract: The invention provides fluorescent schweinfurthin analogs of formula (I) which are useful as probes and for the treatment of cancer and other diseases.

Abstract: The present invention relates to a process for the preparation of 2-substituted 4-hydroxy-4-methyltetrahydropyranols by reacting 3-methylbut-3-en-1-ol (isoprenol) with the corresponding aldehydes in the presence of a strongly acidic cation exchanger. Specifically, the present invention relates to a corresponding process for the preparation of 2-isobutyl-4-hydroxy-4-methyltetrahydropyran by reacting isoprenol with isovaleraldehyde.

Abstract: The present invention relates to the field of catalytic hydrogenation and, more particularly, to the use of specific ruthenium catalysts, or pre-catalysts, in hydrogenation processes for the reduction of ketones and/or aldehydes into the corresponding alcohol respectively. Said catalysts are ruthenium complexes comprising a tetradentate ligand (L4) coordinating the ruthenium with: —two nitrogen atoms, each in the form of a primary or secondary amine (i.e. a NH2 or NH group) or N-alkyl imine functional groups (i.e. a C?N group), and —two sulfur atoms, each in the form of thioether functional groups.

Abstract: A dianhydrohexitol diester composition is obtained by esterifying a dianhydrohexitol composition with a carboxylic acid in the presence of an acid catalyst and hypophosphorous acid. Preferably, the hypophosphorous acid is introduced in an amount between 0.05 and 2 wt. percent of dianhydrohexitol, and in a hypophosphorous acid/acid catalyst weight ratio of less than 1/1. Dianhydrohexitol diester compositions, for example isosorbide diesters, isomannide and/or isoidide rich in diester(s), and having a low yellow index (YI), are useful in numerous industrial applications, in particular in plastic compositions.

Abstract: A process for the oxidation of alcohol and/or aldehyde groups with a peroxo compound in the presence of a heterogeneous rhenium based catalyst, and a co-catalyst. The process of the invention may, for example, be applied to the manufacture of maleic acid which can be dehydrated to lead to maleic anhydride.

Abstract: The present invention relates to thiophene containing compounds of formula (I) wherein m, n, p, q, r, s, R1, R2, and R3 are as defined in the description. Included also are pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions.

Abstract: Disclosed herein is novel process for preparation of atovaquone, which process includes reacting 1H-2-benzopyran-1,4(3H)-dione with 4-(4-chlorophenyl)cyclohexanecarbaldehyde. The invention further discloses novel intermediates useful in the preparation of atovaquone.

Abstract: The disclosure provides novel trioxane sulfur dimers having Formula I: methods for their preparation, pharmaceutical compositions containing these compounds, and methods for treating cancer, proliferative disorders, and/or malaria using these compounds and/or compositions.

Abstract: Disclosed herein are compounds of the formula (I) or (II) in which: L is a neutral ligand; X, X? are anionic ligands; R1 and R2 are, separately, a hydrogen, a C1-C6 alkyl, a C1-C6 perhalogenoalkyl, a aldehyde, a ketone, an ester, a nitrile, an aryl, a pyridinium alkyl, an optionally substituted C5 or C6 pyridinium alkyl, perhalogenoalkyl or cyclohexyl, a Cnh2NY radical 10 with n between 1 and 6 and y an iconic marker, or a radical having the formula: wherein R1 can be a radical of formula (Ibis) when the compound has formula (I) or of formula (IIbis) when the compound has formula (II), R3 is a C1-C6 alkyl, or a C5 or C6 cycloalkyl or a C5 or C6 aryl; R0, R4, R5, R6, R7, R8, R9, R10, R11, are, separately, a hydrogen, C1-C6 alkyl, a C1-C6 perhalogenoalkyl, or a C5 or C6 aryl; wherein R9, R10, R11 can be a heterocycle; X1 is anion. R1 and R2 can form, with the N and the C to which they are attached, a heterocycle.

Abstract: A method of synthesizing rottlerin analogs is described. The synthesis methods described are the first known method of synthesizing rottlerin analogs from commercially-available materials to produce cost effective analogs. Rottlerin analog structures made by the synthesis methods and methods of use for treating a neurological or inflammatory response mediated by protein kinase C (PKC) are further described.

Abstract: The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.